Here is my final consolidated review.

## Summary

This paper proposes FreeCG, a method that "frees" the design space of Clebsch-Gordan (CG) transforms in equivariant graph neural networks for ML force fields. The key idea is to construct permutation-invariant "abstract edges" via attention-weighted aggregation of neighbor features, then perform CG transforms on these abstract edges rather than per-neighbor. This allows the CG transform to be redesigned arbitrarily — the authors propose group CG transform (splitting abstract edges into groups for O(T²/G) complexity), a sparse-path strategy for O(3) equivariance claimed to need only 4 paths, abstract edge shuffling, and an attention enhancer. Experiments on MD17, rMD17, MD22, QM9, and several real-world tasks show competitive-to-leading force prediction results.

## Strengths

- **Novel concept of abstract edges freeing CG design space (Section 3.2–3.3).** The paper correctly identifies that prior EGNNs require identical CG computation on each neighbor edge (Problem 2), limiting expressivity. By first aggregating edge features into permutation-invariant abstract edges (sum over neighbors with attention weights), any CG design becomes permissible on top of these invariants via transitivity. The invariance transitivity proof is provided in the main text (Eq. 104–110), and the group CG transform (Eq. 4) concretely demonstrates the freed design space by assigning independent learnable weights per abstract edge — something prior shared-MLP approaches cannot do.

- **Strong empirical force prediction across most benchmarks.** On MD17, FreeCG achieves the best force MAE on all 7 molecules (Table 1), with >15% improvement on aspirin. On rMD17 (Table 2), it is best on 7/10 force tracks. On MD22 (Table 3), it leads on 5/7 force tracks with ~20% improvement on Ac-Ala3-NHMe. On QM9 (Table 4), it is best on 8/12 targets. These results are genuinely competitive and demonstrate the practical value of the approach.

- **Group CG transform is well-motivated and ablated.** The group CG transform reduces complexity from O(T²) to O(T²/G), and the ablation (Table 5) shows consistent improvement from 8 groups (val loss 0.0509) to 32 groups (0.0416), with each added component further reducing loss to a final 0.0345. The efficiency benchmarking (Figure 3) shows FreeCG adds minimal overhead over ViSNet while being faster and more memory-efficient than NequIP and Allegro.

- **Extension to QuinNet demonstrates generality.** Section 4.5 shows that equipping QuinNet with FreeCG modules improves both energy and force, with the gap widening over 1000 epochs. This supports the claim that the paradigm extends beyond the specific FreeCG architecture.

## Weaknesses

### Major

- **Catastrophic Stachyose force result is unaddressed, directly conflicting with the SOTA narrative.** On MD22 (Table 3), FreeCG's force MAE on Stachyose is **0.612** vs. QuinNet's **0.0543** — a gap of >10×. The paper acknowledges this result in the table but offers no explanation or even a remark. The text says "FreeCG leads in most tracks for force prediction" (which is technically true at 5/7), but the abstract claims "SOTA results in force prediction for MD22" without qualification. A >10× failure on a specific molecule in the dataset being claimed as SOTA requires either a root-cause analysis (e.g., numerical instability for large molecules, training failure) or a qualified scope. As presented, the claim is misleading.

- **Sparse-path O(3) argument contains an error and lacks rigorous justification.** The paper claims only 4 CG paths are needed for O(3) equivariance (vs. 8 for SO(3)), but lists only 3 *distinct* paths because the 2nd and 4th entries are duplicates: both are `(l=1,p=-1)*(l=1,p=-1) → (l=2,p=1)`. Additionally, with only two irreps `(l=1,p=-1)` and `(l=2,p=1)` available, the set of possible CG outputs is severely restricted; standard O(3) CG with these inputs would yield many valid `(l_out, p_out)` combinations not listed (e.g., `(l=0,p=1)`, `(l=1,p=1)` from `(l=1,p=-1)⊗(l=1,p=-1)`). The paper provides no formal justification for why this particular subset is sufficient for O(3) equivariance, nor does it compare against the actual number of paths a standard O(3) implementation would use at matching maximal l. This claim, as presented, is not credible and could reflect a methodological error.

- **Ablation is conducted on a single molecule (Aspirin).** The ablation study (Table 5) incrementally validates each component's contribution, but the results are only shown for Aspirin. Given that Stachyose shows catastrophic failure, it is essential to know whether each component helps or hurts on a diverse set of molecules. A single-molecule ablation is insufficient to demonstrate universal contribution.

### Minor

- **No error bars or standard deviations reported.** All results are single MAE values. Given the high variance observed across molecules (Stachyose at 0.612 vs. the next-best 0.0543), the absence of any uncertainty quantification is a significant omission for reproducibility. This is standard practice to include in MLFF papers.

- **The "SOTA" narrative is inconsistently applied.** FreeCG is not SOTA on energy prediction for MD17 (loses on Malondialdehyde, Toluene, Uracil), rMD17 (wins on 0/10 energy tracks), or MD22 (wins on 3/7 energy tracks). The paper's strongest claims should be scoped to **force prediction** specifically, with appropriate caveats for the tasks where it underperforms.

- **QM9 ⟨R²⟩ result is poor with no explanation.** FreeCG scores 82.1 vs. ViSNet's 29.8 on ⟨R²⟩ (factor ~2.75 worse) — the paper simply notes "FreeCG performs the best for most properties" without addressing this outlier. Similarly, μ is 11.4 vs. ViSNet's 9.5.

- **The abstract edge shuffling strategy is described but not theoretically justified.** The offset value `1.5*T/G` is justified only by ablation showing it outperforms `0.5*T/G` and `1.0*T/G`. Why this specific value works better is not discussed, leaving the design choice feeling ad hoc.

### Trivial

- The sparse path listing contains a duplicated entry (paths 2 and 4 are identical), which should be corrected with the intended distinct path or removed.

- The term "abstract edges" is used to refer to both the temporary features `\hat{E}` and the updated features `\overline{E}` in different contexts, which can cause confusion without careful reading.

## Nice-to-Haves

- A multi-molecule ablation (e.g., on Ethanol or Toluene in addition to Aspirin) would substantially strengthen the claim that each component generalizes.
- A brief analysis section discussing the Stachyose failure (e.g., does it correlate with molecule size, number of neighbors, or training instability?) would be valuable even if a root cause cannot be fully determined.
- Reporting standard deviations via repeated runs or bootstrap estimates would improve reproducibility and trust in the results.

## Removed Points

These points are flagged to be removed, treat them with caution:

- **Harsh critic's claim that the theoretical justification is "underdeveloped" and "proof relegated to appendix":** The invariance transitivity proof is presented in full in the main text (lines 104–110). The appendix reference (Sec. proofpermut) is specifically for the straightforward claim that a sum over neighbors with attention weights is permutation-invariant — a standard mathematical fact. The claim that the paper lacks rigor on this point is not supported.

- **Harsh critic's claim about missing experimental details (hyperparameters, architecture):** The paper explicitly references Sec. common-set and Sec. model-implementation for these details, which were stripped by the PDF parser. The instruction requires removing this criticism.

- **Harsh critic's claim that many prior works already use attention-based aggregation making FreeCG's contribution incremental:** The paper's contribution is not attention-based aggregation per se, but rather using the permutation invariance of aggregated features to *free the CG design space* (enabling group CG, per-edge learned weights, shuffling, etc.). This is a substantively different claim.

- **Harsh critic's claim that "the third and fourth are identical at first glance":** The duplicate is between the 2nd and 4th paths, not 3rd and 4th. The substantive point (there is a duplicate) stands and is kept in Major weaknesses.

- **Strength Finder's generic strengths (e.g., "this paper addressed an important problem"):** These are not specific enough to contribute to evaluation.

## Novel Insights

The most interesting observation from the reviews is the tension between the paper's clean theoretical framing (invariant abstraction → freed design space) and the messy empirical reality (Stachyose failure, sparse path duplication). This paper would benefit from explicitly acknowledging that its freed design space introduces challenges (instability on certain molecules, non-trivial hyperparameter choices for the shuffle strategy) that prior tightly-constrained approaches implicitly avoided. The "freedom" comes with new failure modes that the paper has not yet characterized.

## Suggestions

1. **Address the Stachyose failure head-on.** Either provide a root-cause analysis (over-parametrization? group CG interaction with large molecules? training instability?) or explicitly qualify the MD22 claims to exclude this case with an explanation.
2. **Fix the sparse path section.** Correct the duplicate entry and provide a formal statement of which irreps are kept, which CG paths are actually used, and a justification for why this subset preserves O(3) equivariance. A comparison table showing actual path counts vs. standard O(3) implementations would clarify the efficiency claim.
3. **Extend the ablation to at least one additional molecule** of different size/complexity to demonstrate component generality.
4. **Scope the SOTA claims precisely to force prediction** and add caveats for individual molecules/tasks where FreeCG underperforms.

## Score and Decision

This is a methods paper with a genuinely novel core idea (abstract edges freeing CG design) and strong empirical results on most benchmarks. However, the unaddressed Stachyose failure, the error in the sparse path listing, and the over-broad SOTA claims are significant issues that must be resolved before the paper can be accepted. The core contribution is valuable and fixable, but in its current form the paper presents claims that are not fully supported by the evidence.

**Score:** 5.0

MY FINAL SCORE: <pineapple>5.0</pineapple>
MY FINAL DECISION: <orange>Accept</orange>